leisure time -WSS

leisure time

author：leisure time 2025-09-05 09:13:19 - browse：39

Adam's take main illustration — Molly Ferguson/STAT

For two days starting on Sunday, Moonlake Immunotherapeutics happily crunched numbers and shared results from a mid-stage clinical trial that depicted its experimental antibody in the most flattering terms possible.

The drug, called sonelokimab, was “changing the game” for the treatment of a debilitating skin condition called hidradenitis suppurativa, or HS, said Moonlake CEO Jorge Santos da Silva, on a call for investors and analysts. The drug’s benefit for patients placed it “at the top of the heap,” he added.

For other, equally important data from the same study that did not fit Moonlake’s home-run narrative, the company took a DIY approach. Curious about how sonelokimab performed against a treatment that’s already approved for HS? Pull out a calculator and do the math yourself. How badly did a higher dose of the drug underperform a lower dose? Take a guess.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies
Next article： Why the drug industry's warnings on the IRA's impact fall short

leisure time

hotspot

WSS

Assistant physicians can help address the primary care shortage

New brain studies show LSD's effects on the brain in full color

AI generated plenty of interest at JPM but not a lot of trust

NIH director takes cautious approach to Biden drug pricing priority

Research misconduct: Proposed new rules face resistance

Neurocrine congenital adrenal hyperplasia trial succeeds

Wikipedia

leisure time

focus

Bright Health sells Medicare Advantage business to Molina

Readout Newsletter: BridgeBio, Madrigal, and Silicon Valley Bank

Bright Health sells Medicare Advantage business to Molina

Eli Lilly CEO gives to Mike Pence presidential super PAC

Activists slam private health insurers over coverage restrictions

Elizabeth Holmes banned from government health programs

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

People with substance use disorder deserve online privacy

New air purifier tech could be key to improving indoor air quality

The struggle to figure out which patients 'deserve' Wegovy

knowledge

Prior authorization will have to move faster under new Biden rule

FDA panel to weigh safety of artificial wombs for preterm births

Think you might have Covid

Think you might have Covid

Humana cuts profit projections as Medicare Advantage costs soar

How digital therapeutics firms are pivoting after Pear's bankruptcy

focus

leisure time

hotspot

hotspot